Login
- Document type:
- Journal Article; Review
- Author(s):
- Ettl, Johannes
- Title:
- Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.
- Abstract:
- Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed.
- Journal title abbreviation:
- Breast Care (Basel)
- Year:
- 2016
- Journal volume:
- 11
- Journal issue:
- 3
- Pages contribution:
- 174-6
- Language:
- eng
- Fulltext / DOI:
- doi:10.1159/000447417
- Pubmed ID:
- http://view.ncbi.nlm.nih.gov/pubmed/27493616
- Print-ISSN:
- 1661-3791
- TUM Institution:
- Frauenklinik und Poliklinik
BibTeX